Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Janssen Biotech (Details)

v3.22.4
Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2021
May 31, 2021
Aug. 31, 2019
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2019
Licensing and other arrangements            
Revenue from contracts with customers       $ 4,150 $ 36,518  
Janssen Biotech Inc. | License Agreement            
Licensing and other arrangements            
Cash payment received     $ 2,500      
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events     $ 3,000      
Percentage of royalty on worldwide net sales of each product upon commercialization     0.75%      
Revenue from contracts with customers $ 200 $ 500   0 700 $ 2,500
Contract assets 0     0 0  
Contract liabilities 0     0 0  
Capitalized contract costs $ 0     $ 0 $ 0